<br>        Inclusion Criteria:<br><br>          1. All cancer patients treated with anthracyclines<br><br>          2. Informed consent must be obtained from the patient<br><br>          3. Patients suspected to have been exposed to extravasation (leakage) of anthracycline,<br>             defined as:<br><br>               1. A primary assessment by the physician on duty, which would activate the standard<br>                  departmental procedure for treatment of anthracycline extravasation.<br><br>               2. The presence of at least one of the following symptoms: pain, swelling or<br>                  redness at the site where the anthracycline leakage is suspected to have<br>                  occurred.<br><br>          4. Suspicion of anthracycline extravasation from a central venous access device<br><br>          5. The Topotect® infusion must be started < 6 hours after the accident<br><br>          6. 18 years of age or older<br><br>          7. Performance status (PS) < 2<br><br>        Exclusion Criteria:<br><br>          1. Known allergy towards dexrazoxane<br><br>          2. Reasonable suspicion of extravasation by other compounds than anthracyclines through<br>             the same intravenous access, e.g. vincristine, mitomycin, and vinorelbine, all of<br>             which may cause ulceration<br><br>          3. AST (aspartate aminotransferase) or ALT (alanine aminotransferase), bilirubin, LDH<br>             (lactate dehydrogenase), alkaline phosphatase >3 x upper normal value<br><br>          4. Neutrophils CTC (common toxicity criteria) = grade 2. (neutrophils 1.5 x 109/L,<br>             =1,500/mm3)<br><br>          5. Platelets CTC = grade 2. (platelets =75.0 x 109/L, <75,000/mm3).<br><br>          6. Topical use of DMSO (dimethylsulfoxide) at the area of the accident<br><br>          7. Administration of dexrazoxane within the last 3 weeks<br><br>          8. Pregnant or nursing women<br><br>          9. Women of childbearing age and potential, who do not use an efficient contraceptive<br>             (e.g. the Pill or a diaphragm plus a spermicide) for at least 3 months prior to the<br>             start of trial medication<br>